Ivytan

Ivytan (Beijing) Biopharmaceutical is a clinical-stage biotechnology company based in China that specializes in the discovery and development of precision oncology therapeutics. As a core subsidiary of Avistone Biotechnology, the company focuses on targeting the c-Met signaling pathway to treat various forms of cancer. Its lead product, vebreltinib (also known as IVT-8001 or SCC244), is a highly selective c-Met inhibitor that received conditional marketing approval from China's NMPA in 2023 for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Beyond lung cancer, Ivytan is advancing clinical programs for vebreltinib in glioblastoma and other MET-driven solid tumors. The company leverages its deep expertise in medicinal chemistry and molecular biology to address significant unmet medical needs in the field of targeted cancer therapy.